All News

Dual IL-17A/F inhibition with Bimekizumab reduced MRI inflammatory change in the SIJ and spine in AxSpA, and increasing proportion achieving MRI remission at Wk52, Abst#POS0246 #EULAR2023 @RheumNow https://t.co/w4VkkUklGl
Dr. Antoni Chan synovialjoints ( View Tweet)
Jun 03, 2023
Chinese study 43 axSpA pts Rx w/ Secukinumab-37 pts had HBV & 16% (6) reactivated HBV after mean 9 mos of SEC (5 w/ chronic HBV, 1 occult HBV). 2 pts chronic HBV reactivated despite anti-HBV prophylaxis. 6 axSpA w/ LTBI - none had TB on SEC https://t.co/o4gA9mcD2R https://t.co/XKwp2z9U3K

Links:

Dr. John Cush RheumNow ( View Tweet)
May 31, 2023
Convention1.jpg

EULAR 2023: Featured Industry Presentations

d Jack Cush, MD
May 30, 2023

EULAR 2023 opens tomorrow, Wednesday May 31st, with hundreds of novel presentations and pivotal clinical trials, many being featured industry sponsored clinical trials and research on their novel agents. Below is a collection of the featured abstracts, and presentation times from EULAR 2023. 

Read Article
Rheumatoid,RA,nodules,damage

Prevalence of Psoriatic Arthritis, Spondyloarthritis and Rheumatoid Arthritis in Norway

d Jack Cush, MD
May 25, 2023

Recent reports have suggested a rising and unrecognized number of patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) compared to rheumatoid arthritis (RA).

Read Article
Bimekizumab is a dual IL-17A and IL-17F inhibitor, for nr-axSpA and AS - it works but is it different from existing IL-17i? - appears to work well in TNFi-inadequate responders - are TNFi-IR pts immunologically different? #RNL2023 https://t.co/bHboX3Xz6M https://t.co/kCa9MbFdxs

Links:

Dr. John Cush RheumNow ( View Tweet)
May 25, 2023
SI AS SpA ACR

ICYMI: Spondyloarthritis Innovations

d Robert Chao, MD
May 22, 2023

The second day of RheumNow Live 2023 held in March ended with a focus on axial spondyloarthritis, especially on the evaluation of the definition of the disease, the inheritance of it, and of course the treatment of it.

Read Article
PSA068.jpg

Disappointing Secondary Use of Newer Therapies in Psoriatic Arthritis

d Jack Cush, MD
May 12, 2023

Analysis of patient data from five Nordic registries shows that the uptake of newer biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in psoriatic arthritis (PsA) was mainly in biologic-experienced patients.

Read Article
RheumNow Podcast square

The Match Game (4.14.2023)

d Jack Cush, MD
Apr 14, 2023

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, including Rheumatology success in the NRMP MATCH, Cocaine vasculitis and worrisome safety risks with Biologics and tsDMARDs.

Read Article
FDA FAERS study of IL-17 inhib & colitis: 388 pts w/ suspected IL-17i assoc. IBD. Median age - 42 yrs; Initial Sxs= diarrhea 91%, Abd pain 58%, bloody diarrhea 51%), & fever 36%, ^WBC 87%; Time to onset=2.9 mos. Time to remission after IL-17i D/C =4 wks https://t.co/adrtUhFj9C https://t.co/61GC5hvzYV

Links:

Dr. John Cush RheumNow ( View Tweet)
Apr 12, 2023
RheumNow Podcast square

Night Splinting for Carpal Tunnel (3.24.2023)

d Jack Cush, MD
Mar 24, 2023

Dr. Jack Cush reviews the news and journal articles from the past 2 weeks on RheumNow.com.  This week reviews clinical associations with SS-A, a new biomarker for SSc-ILD and cancer screening for myositis patients.

Read Article
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/MMHvtkbz9l https://t.co/3aNijNJWkW

Links:

Dr. John Cush RheumNow ( View Tweet)
Mar 22, 2023
SI AS SpA ACR

Spondyloarthritis Innovations

d Robert Chao, MD
Mar 21, 2023

The second day of RheumNow Live 2023 ended with a focus on axial spondyloarthritis, especially on the evaluation of the definition of the disease, the inheritance of it, and of course the treatment of it.

Read Article
Future treatment for #AxSpA ? Promising data for #Bimekizumab Inhibits IL-17 A and F #RNL2023 https://t.co/H2euMPgIFj
Dr Gurdeep Dulay gurdeep_dulay ( View Tweet)
Mar 19, 2023
No significance difference in radiographic progression in patients with IL17-TNF , BY Atul Deodhar #RNL2023 ⁦@RheumNow⁩ https://t.co/S3NQ4mWgjt
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Mar 19, 2023
SURPASS: SEC vs ADA for axSpA Outcome: %pts with no radiographic progression Not benefit- Secukinumab not better than adalimumab Though negative study, in all groups the progression was very low (<1 mSASS) - both interventions did well! @RheumNow #RNL2023 https://t.co/Vt58jSXCMd
Eric Dein ericdeinmd ( View Tweet)
Mar 19, 2023
Late breaking ACR abstract '22 SURPASS study (H2H TNFi vs IL17 in AS radiographic progression.) Primary endpoint was not met. However, Dr. Deodhar's take away: spinal radiographic progression over 2 years is very low despite high disease activity in both txs! #RNL2023 @RheumNow https://t.co/TsukRs29pC
Dr. Rachel Tate uptoTate ( View Tweet)
Mar 19, 2023
Bimekizumab is a dual IL-17A and IL-17F inhibitor, for nr-axSpA and AS - it works but is it different from existing IL-17i? - appears to work well in TNFi-inadequate responders - are TNFi-IR pts immunologically different? niche category for IL-17A and F use? @RheumNow #RNL2023 https://t.co/dWkakahHAi
Robert B Chao, MD doctorRBC ( View Tweet)
Mar 19, 2023
#RNL2023 Year in Review New Drugs in Old Disease? GCA - Tocilizumab (GiACTA ), Secikinumab (TitAIN), Mavrilimumab (GM-CSFr mAb) PMR - Sarilumab (SAPHYR), TCZ (PMR-Spare, SEMAPHORE), Tofacitinib (EAST PMR) @RheumNow https://t.co/cY2HuaI6uM
Eric Dein ericdeinmd ( View Tweet)
Mar 19, 2023
An exciting year and time for GCA and PMR treatment! - Tocilizumab (IL-6i) - Secukinumab (IL-17i) - Sarilumab (IL-6i) - Mavrilimumab (GM-CSF receptor mAb) - Tofacitinib (JAKinib) @RheumNow #RNL2023 https://t.co/d0T2RAssFY
Robert B Chao, MD doctorRBC ( View Tweet)
Mar 19, 2023
#RNL2023 Year in Review BE COMPLETE: P3 trial Bimekizumab for PsA in TNF inadequate responses at 16 weeks 160 mg BKZ SQ q4w vs PBO ACR50 43%, PBO 7% PASI 1000: BKZ 58.5% vs PBO 4.5% Safety: oral candidiasis: 2.6% BKZ vs PBO 0% @RheumNow https://t.co/bW00Wg6Cnf
Eric Dein ericdeinmd ( View Tweet)
Mar 19, 2023

    Do you get our email newsletter?

    Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

    Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

    Copyright 2023 All Rights Reserved.

    ×